TheraRadar
← Back
Data updated: Mar 29, 2026

SHANDONG

MetabolicOncologyCardiovascular
Generics

SHANDONG is a generic drug manufacturer focused on Metabolic, Oncology, Cardiovascular.

2018
Since
11
Drugs
-
Trials
141
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

OSELTAMIVIR PHOSPHATE 2026-01-22
OXALIPLATIN 2026-01-15
OSELTAMIVIR PHOSPHATE 2026-01-15
Labeling
ROCURONIUM BROMIDE 2026-01-06
ISOFLURANE 2025-11-04
ROCURONIUM BROMIDE 2025-10-24
OXALIPLATIN 2025-10-22
Labeling
SEVOFLURANE 2025-10-02
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 40%
0 drugs Phase 3: 7 Phase 2: 5 Phase 1: 13
Oncology 34%
0 drugs Phase 3: 4 Phase 2: 5 Phase 1: 18
Cardiovascular 16%
2 drugs Phase 3: 1 Phase 2: 2
Gastroenterology 8%
0 drugs Phase 3: 1 Phase 2: 3
Respiratory 3%
0 drugs Phase 3: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Metabolic
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Cardiovascular
BRACCO specialty
Cardiovascular, Oncology, Metabolic, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Metabolic